Background. One in five people affected by depression will not recover fully from a first episode, and in 70-80% of those achieving remission, depression will recur. The aim of this study was to evaluate the consumption of antidepressants during six years (2004)(2005)(2006)(2007)(2008)(2009) in Lithuania, to analyze the trends in the diagnosis of depression and its compliance with the use of antidepressants for the future investigation of rationalizing medicamentous depression treatment costs in Lithuania opportunities.
common. The National Institute for Health and Clinical Excellence estimates that 9.8% of presons 16 to 65 years old in the UK are suffering from mixed depression and anxiety (4) . One in five people affected by depression will not recover fully from a first episode, and in 70-80% of those achieving remission, depression will recur at least once. The long-term recurring nature of depression magnifies its wider economic burden (5, 6) .
In recent years, an increasing number of cases of recurrent depression is recorded, which greatly increases the overall number of patients with this disease. The number of suicides also increases together with the spreading depression; e. g., 59 thousand of people killed themselves because of the impact of depression in 2006 in the whole Europe (7).
The use of antidepressants has increased in all Western countries during the past 15-20 years. The defined daily dosages were developed as a tool for presenting drug consumption figures and have been used for many years in drug utilization studies where they are useful for both national and international comparisons of drug consumption and the evaluation of long-term trends in drug use. In Finland, the increase between 1990 and 2006 was nearly 8-fold (8), i. e. from 7.09 defined daily doses (DDD) expressed for 1 000 inhabitants a day in 1990 to 55.47 DDDs in 2006. Similar trends have been reported elsewhere (9) . Although the consumption of antidepressants at the population level has increased notably, population-based studies with all psychotropics and antidepressants in particular suggest that increased prescribing may not have markedly improved the mental health of the population. In Scotland, for example, national development targets have already been made for reducing the increase in antidepressant use. On the other hand, underutilization of antidepressants among the depressed remains a constant concern since epidemiological evidence shows that depressive individuals do not receive the care they need. Further, the impact of antidepressant utilization rates on suicides is discussed (10) .
The aim of this study was to assess the antidepressant consumption patterns in six years (2004) (2005) (2006) (2007) (2008) (2009) 
MAteRIALs And Methods
Data on the total sales of antidepressant drugs in all Lithuanian regions over six years (2004) (2005) (2006) (2007) (2008) (2009) were obtained from the IMS (Intercontinental Marketing Service) Health Incorporated. The data were retrieved as units of antidepressant drugs and their costs. The system and use were quantified in terms of defined daily doses (DDDs).
The most widely accepted method for measuring medicine consumption is the defined daily dose (DDD). This method was adopted by the World Health Organization (WHO) more than 20 years ago as a means to standardize drug utilization research among countries (11) . The DDD theoretically corresponds to the average daily maintenance dose for a drug's major indication. The WHO has defined and periodically updates the DDD for most antibiotics available in the United States; these definitions are available free of charge on the Internet (12) . The DDD / 1000 patient-days measurement has its limitations. For example, the DDD values are based on typical dosages for adult populations with the normal renal function. In institutions with large populations of children or patients undergoing dialysis, traditional DDD measurements may not accurately mirror the patient-level use of medicines (13) . Occasionally, the DDDs do not reflect common dosages utilized in specific institutions or doses actually dispensed (14) .
The defined daily dosages were developed as a tool for presenting drug consumption figures and have been used for many years in drug utilization studies where they are useful for both national and international comparisons of drug consumption and the evaluation of long-term trends in drug use (15) . Drug consumption figures serve as a basis for the identification and evaluation of factors influencing the level of drug use.
Data were calculated by the DDD methodology and expressed in DDDs per 1.000 inhabitants per day. The DU95% was used as the quality indicator of drug prescribing. The number of drugs contributing to 95% of sales as a proportion of the total number was calculated for each year.
Data on depression diagnoses were obtained from the National Psychiatric Health Centre and expressed in total diagnoses and by depression types and gender.
ResuLts
The total consumption of antidepressant drugs in Lithuania increased by 48% in six years (from 10.17 DDD/1000 inhabitants / day in 2004 to 15.10 DDD / 1000 inhabitants / day in 2009) ( Fig. 1) .
Changes of consumption within antidepressant classes in six years (2004) (2005) (2006) (2007) (2008) (2009) ) are the following ( Fig. 1): • the proportion of consumption of TCAs declined by 42% (from 2.03 to 1.18 DDD / 1000 inhabitants / day);
• the consumption of SSRIs showed a pronounced increase of 45% (from 6.38 to 9.25 DDD / 1000 inhabitants / day); therefore, SSRIs were the most widely used antidepressants;
• the consumption of newest drugs classified as "other antidepressants" increased significantly (almost three times) over the study period (from 1.61 to 4.63 DDD / 1000 inhabitants / day). However, this is associated with the expanded use of mirtazapine, tianeptine, buproprion and venlafaxine as in 2004 buproprion and venlafaxine have appeared in the antidepressants segment;
• there were modest changes in the consumption of lithium.
A comparison of the proportions of different antidepressant classes has shown that the proportion of SSRIs remained almost the same (62%), although their consumption has increased, while the proportion of other (newer) antidepressants increased almost two times and comprised 31% of the total market.
Over the study period, the consumption of sertraline remained on the top of the list. Besides, the results show that the proportion of sertraline consumption decreased from a quarter of all antidepressants (24.5%) to 22.6%, and in parallel the proportion of amitryptiline consumption declined more than by half -from 14.33% to 6.71%. The use of paroxetine, mirtazapine and escitalopram increased, whereas the use of other SSRIs (fluoxetine, citalopram, fluvoxamine) decreased.
The number of total depression diagnoses increased from 20 (Fig. 2) .
The results show that in 2009 women were diagnosed with depression 4.5 times more frequently than men. Moreover, depression relapse numbers grew up by 33% during the study years among women, while in men the number of relapsed depression cases was almost the same (Figs. 3, 4) . Each year there are more cases of depression diagnosed in Lithuania. The statistics of diseases demonstrates a continuously increasing number of recurrent depression diagnoses.
According to data of researchers from the University of Virginia (USA), this disorder is recurrent even for 50% of those with depression and those who have been treated.
Other figures are more daunting: after a repetitive treatment of depression, about 70% of patients and after three treatments even 90% fall into depression for the third time. Each recurring disease means that a previous treatment was unsuccessful (16) .
The biggest impact on consumption growth was made by the use of SSRIs and the newest "other antidepressants". The increased use of selective serotonin reuptake inhibitors and other nontricyclic antidepressants is probably related to their better tolerability, an improved risk-to-benefit ratio and lower toxicity in case of overdosage. The proportion of different antidepressants classes also surprises: during studied six years the proportion of SSRIs remained almost the same, while the proportion of newer "other" antidepressants grew up almost two times. Over the study period, the consumption of sertralin remained on the top of the antidepressant consumption list, followed by the newest antidepressants such as paroxetine, mirtazapine and escitalopram. In this situation, a hypothesis arises that the reason for depression relapse growth may be the consumption of modern and newest medicines.
Also, the results show that women were diagnosed with depression more frequently than men. Moreover, depression relapse numbers in women increased drastically.
These data are consistent with data on a higher prevalence of depression in females (17) (18) (19) . However, women do not experience more mental diseases than men; they are simply more prone to depression and anxiety, whereas men are more likely to have addictive disorders and personality disorders (20) . The effects of stress, violence, poverty, inequality, sexism, care giving, relational problems, low selfesteem, and ruminative cognitive styles probably increase vulnerability to depression in women (21) . Predictive factors for depression include previous depression, feeling out of control or overwhelmed, chronic health problems, traumatic events in childhood or young adulthood, lack of emotional support, lone parenthood, and low sense of mastery (22) . Special considerations are required for analyzing the risk factors influencing the women's physical health (23) .
Our results confirm the findings reported in the literature that there is a gender gap in depression across Europe. Socioeconomic factors as well as family-related characteristics moderate the relationship between gender and depression. The largest gender differences in depression were found in a number of Southern European and in certain Eastern European countries (24) .
The impact of depression on society has not yet been assessed in Lithuania. This disease carries a considerable epidemiological impact and is often both misdiagnosed and mistreated; depression imposes an enormous burden on society, resulting from its high prevalence, under-diagnosis and under-treatment. Depression implies many costs and consequences, including a decreased quality of life for patients and their families, high morbidity and mortality, and substantial economic losses (25) .
Thus, as regards depression and other major chronic illnesses, it is important to consider the global disease management. Hence, a proper use of all the remedies available to date can really improve not only the clinical but also the economic component of the management of patients suffering from depression, thus producing global savings for the health system (26) .
concLusIons
The increasing consumption of antidepressants and the growing numbers of depression diagnoses induce the necessity of a deeper analysis of the causes of this disease -physiological, psychological, social ones. Results of a comparison of the first-time and relapsed depression diagnoses are surprising: the level of first-time depression diagnoses remains almost the same, whereas relapsed depression numbers grow up significantly in all years of the study. The results of our study show that the number of depression diagnoses increases because of depression relapse in women.
Additional studies should be carried out in order to assess the true economic burden of depression treatment and especially the impact of its relapse on society.
